{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:59:21Z","timestamp":1788919161132,"version":"build-2803163510"},"reference-count":212,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Methods"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ymeth.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:22:17Z","timestamp":1739406137000},"page":"100-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Latest trends & strategies in ocular drug delivery"],"prefix":"10.1016","volume":"235","author":[{"given":"Nishant S.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Josowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindhu","family":"Rayaprolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botir","family":"Sagdullaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amardeep S.","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Shameem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymeth.2025.02.003_b0005","unstructured":"CDC. Vision and Eye Health. 2024 [cited 2024 Jul 26]. About Common Eye Disorders and Diseases. Available from: https:\/\/www.cdc.gov\/vision-health\/about-eye-disorders\/index.html."},{"key":"10.1016\/j.ymeth.2025.02.003_b0010","unstructured":"Vyawahare H, Shinde P. Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Cureus. 14(9):e29583."},{"issue":"21","key":"10.1016\/j.ymeth.2025.02.003_b0015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"22","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0020","unstructured":"American Academy of Ophthalmology [Internet]. 2018 [cited 2024 Jul 26]. The Eye and Immune Privilege. Available from: https:\/\/www.aao.org\/eye-health\/tips-prevention\/eye-immune-privilege."},{"key":"10.1016\/j.ymeth.2025.02.003_b0025","article-title":"Melatonin maintains inner blood-retinal barrier by regulating microglia via inhibition of PI3K\/Akt\/Stat3\/NF-\u03baB signaling pathways in experimental diabetic retinopathy","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0030","first-page":"976","article-title":"Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy","volume":"18","author":"Tang","year":"2022","journal-title":"Neural Regen. Res."},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0035","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/acs.molpharmaceut.1c00236","article-title":"Mechanistic model for the prediction of small-molecule vitreal clearance combining diffusion-limited and permeability-limited clearance","volume":"18","author":"Rimpel\u00e4","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymeth.2025.02.003_b0040","unstructured":"Ophthalmology | FDA Approved Drugs | CenterWatch [Internet]. [cited 2024 Jul 26]. Available from: https:\/\/www.centerwatch.com\/directories\/1067-fda-approved-drugs\/topic\/104-ophthalmology."},{"key":"10.1016\/j.ymeth.2025.02.003_b0045","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.2147\/DDDT.S378450","article-title":"Brolucizumab for the treatment of degenerative macular conditions: a review of clinical studies","volume":"16","author":"Karasavvidou","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"issue":"10326","key":"10.1016\/j.ymeth.2025.02.003_b0050","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/pharmaceutics15010205","article-title":"Ocular delivery of therapeutic proteins: a review","volume":"15","author":"Shastri","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0060","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3390\/cells10092483","article-title":"Potential therapeutic candidates for age-related macular degeneration (AMD)","volume":"10","author":"Nashine","year":"2021","journal-title":"Cells."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ymeth.2025.02.003_b0070","doi-asserted-by":"crossref","unstructured":"Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology [Internet]. [cited 2024 Jul 26]. Available from: https:\/\/bjo.bmj.com\/content\/94\/1\/2.long.","DOI":"10.1136\/bjo.2009.159160"},{"issue":"12","key":"10.1016\/j.ymeth.2025.02.003_b0075","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymeth.2025.02.003_b0080","doi-asserted-by":"crossref","unstructured":"Rinaldi M, Chiosi F, Dell\u2019omo R, Romano MR, Parmeggiani F, Semeraro F, et al. Intravitreal Pegaptanib Sodium (MACUGEN) For Treatment of myopic choroidal neovascularization: a morphologic and functional study. RETINA. 2013 Feb;33(2):397.","DOI":"10.1097\/IAE.0b013e318261a73c"},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0085","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0090","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/molecules21081002","article-title":"Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular Delivery","volume":"21","author":"Mahlumba","year":"2016","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular Drug Delivery: a Comprehensive Review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/24741264221150345","article-title":"High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept","volume":"7","author":"Nielsen","year":"2023","journal-title":"J Vitreoretin Dis."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0110","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/pharmaceutics15061746","article-title":"Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases","volume":"15","author":"Mostafa","year":"2023","journal-title":"Pharmaceutics."},{"issue":"608","key":"10.1016\/j.ymeth.2025.02.003_b0115","article-title":"Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration","volume":"25","author":"Maulvi","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4103\/IJO.IJO_2166_23","article-title":"Off-label use of intravitreal bevacizumab: A global conundrum","volume":"72","author":"Singh","year":"2024","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0125","unstructured":"Off-label intravitreal Brolucizumab in the management of central serous chorioretinopathy - PMC [Internet]. [cited 2024 Aug 29]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10941931\/."},{"issue":"3","key":"10.1016\/j.ymeth.2025.02.003_b0130","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1159\/000510114","article-title":"Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab","volume":"11","author":"Britton","year":"2020","journal-title":"Case Rep Ophthalmol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0135","doi-asserted-by":"crossref","unstructured":"Peng W yan, He L wen, Yin X fang, Zhou BB, Zhou T, Zhou S you. Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns. Front Med [Internet]. 2023 Jun 22 [cited 2024 Jul 30];10. Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2023.1210765\/full.","DOI":"10.3389\/fmed.2023.1210765"},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/ACI.0000000000000309","article-title":"Emerging therapeutics for ocular surface disease","volume":"16","author":"Bielory","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/sjopt.sjopt_256_23","article-title":"Monoclonal antibodies in neuro-ophthalmology","volume":"38","author":"Keehn","year":"2024","journal-title":"Saudi J Ophthalmol."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0150","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.3390\/pharmaceutics15082059","article-title":"Sustained Inhibition of VEGF and TNF-\u03b1 Achieves Multi-Ocular Protection and Prevents Formation of Blood Vessels after Severe Ocular Trauma","volume":"15","author":"Zhou","year":"2023","journal-title":"Pharmaceutics."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jcma.2014.10.002","article-title":"Corneal neovascularization and contemporary antiangiogenic therapeutics","volume":"78","author":"Hsu","year":"2015","journal-title":"J. Chin. Med. Assoc."},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0160","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s10792-020-01391-8","article-title":"Sustained subconjunctival drug delivery systems: current trends and future perspectives","volume":"40","author":"Rafiei","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-0716-0599-8_7","article-title":"Preparation and Administration of Adeno-associated Virus Vectors for Corneal Gene Delivery","volume":"2145","author":"Song","year":"2020","journal-title":"Methods Mol Biol Clifton NJ."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0170","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41434-018-0035-6","article-title":"Serotype survey of AAV gene delivery via subconjunctival injection in mice","volume":"25","author":"Song","year":"2018","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0175","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/pharmaceutics12080767","article-title":"Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases","volume":"12","author":"Bastola","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ymeth.2025.02.003_b0180","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IJG.0000000000001451","article-title":"Evolving Guidelines for Intracameral Injection","volume":"29","author":"Liebmann","year":"2020","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.ymeth.2025.02.003_b0185","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.63.13.15","article-title":"Intracameral Injection of AAV-DJ.COMP-ANG1 Reduces the IOP of Mice by Reshaping the Trabecular Outflow Pathway","author":"Qiao","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymeth.2025.02.003_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108105","article-title":"Deconstructing aqueous humor outflow \u2013 the last 50 years","volume":"197","author":"Kaufman","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymeth.2025.02.003_b0195","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000320016","article-title":"Antivascular endothelial growth factors in anterior segment diseases","volume":"46","author":"Scholl","year":"2010","journal-title":"Dev. Ophthalmol."},{"issue":"16","key":"10.1016\/j.ymeth.2025.02.003_b0200","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options","volume":"25","author":"Tan","year":"2022","journal-title":"Clin Ophthalmol Auckl NZ."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0205","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/09286586.2020.1792937","article-title":"Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion","volume":"28","author":"Hogg","year":"2021","journal-title":"Ophthalmic Epidemiol."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0210","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/07853890.2022.2064541","article-title":"VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy","volume":"54","author":"Arrigo","year":"2022","journal-title":"Ann. Med."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/pharmaceutics13050701","article-title":"Polymeric Implants for the Treatment of Intraocular Eye Diseases: Trends in Biodegradable and Non-Biodegradable Materials","volume":"13","author":"Garc\u00eda-Estrada","year":"2021","journal-title":"Pharmaceutics."},{"issue":"12","key":"10.1016\/j.ymeth.2025.02.003_b0220","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.3390\/biomedicines11123221","article-title":"Recent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review","volume":"11","author":"Finocchio","year":"2023","journal-title":"Biomedicines."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0225","first-page":"2399","article-title":"Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literaturereview","volume":"260","author":"Singh","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"15","key":"10.1016\/j.ymeth.2025.02.003_b0230","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.21037\/atm-20-4726","article-title":"Gene therapy for inherited retinal diseases","volume":"9","author":"Nuzbrokh","year":"2021","journal-title":"Ann Transl Med."},{"key":"10.1016\/j.ymeth.2025.02.003_b0235","doi-asserted-by":"crossref","unstructured":"Jairath NK, Paulus YM, Yim A, Zhou Y, Parekh BJ, Jairath R, et al. Intra- and post-operative risk of retinal breaks during vitrectomy for macular hole and vitreomacular traction. PLoS ONE [Internet]. 2022 [cited 2024 Jul 30];17(8). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9371285\/.","DOI":"10.1371\/journal.pone.0272333"},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0240","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4103\/1673-5374.306063","article-title":"The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery","volume":"16","author":"Ross","year":"2021","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.17219\/pim\/166413","article-title":"A review on topical ophthalmic drug delivery system: Reference to viscosity enhancer","volume":"54","author":"Pawar","year":"2024","journal-title":"Polym Med."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/ejos.ejos_47_20","article-title":"Study of the efficiency and safety of subconjunctival triamcinolone acetonide in macular edema","volume":"114","author":"Taoufik","year":"2021","journal-title":"J Egypt Ophthalmol Soc."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0255","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2022.0144","article-title":"Intracameral Drug Delivery: A Review of Agents, Indications, and Outcomes","volume":"39","author":"Gautam","year":"2023","journal-title":"J Ocul Pharmacol Ther off J Assoc Ocul Pharmacol Ther."},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0260","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.oret.2020.09.024","article-title":"Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors","volume":"5","author":"Ramos","year":"2021","journal-title":"Ophthalmol Retina."},{"issue":"16","key":"10.1016\/j.ymeth.2025.02.003_b0265","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.3390\/jcm11164717","article-title":"Subretinal Injection Techniques for Retinal Disease: A Review","volume":"11","author":"Irigoyen","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0270","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12886-022-02625-2","article-title":"Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema","volume":"22","author":"Khalil","year":"2022","journal-title":"BMC Ophthalmol."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12886-024-03291-2","article-title":"Comparison of intravitreal preservative-free triamcinolone versus posterior sub-tenon triamcinolone acetonide injection for bevacizumab-resistant diabetic macular edema","volume":"24","author":"Jeon","year":"2024","journal-title":"BMC Ophthalmol."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0280","first-page":"939","article-title":"SUPRACHOROIDAL SPACE INJECTION TECHNIQUE: Expert Panel Guidance","volume":"44","author":"Wykoff","year":"2024","journal-title":"Retina"},{"issue":"607","key":"10.1016\/j.ymeth.2025.02.003_b0285","article-title":"Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies","volume":"25","author":"Mofidfar","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ymeth.2025.02.003_b0290","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.addr.2006.07.024","article-title":"Drug transport in corneal epithelium and blood\u2013retina barrier: Emerging role of transporters in ocular pharmacokinetics","volume":"58","author":"Mannermaa","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: An overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J Pharmacol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000455276","article-title":"Drug Delivery to the Posterior Segment of the Eye","volume":"58","author":"Moisseiev","year":"2017","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0305","doi-asserted-by":"crossref","unstructured":"Campbell M, Humphries P. The Blood-Retina Barrier. In: Cheng CY, editor. Biology and Regulation of Blood-Tissue Barriers [Internet]. New York, NY: Springer; 2013 [cited 2025 Jan 17]. p. 70\u201384. Available from: https:\/\/doi.org\/10.1007\/978-1-4614-4711-5_3.","DOI":"10.1007\/978-1-4614-4711-5_3"},{"issue":"57","key":"10.1016\/j.ymeth.2025.02.003_b0310","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"1","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"issue":"10","key":"10.1016\/j.ymeth.2025.02.003_b0315","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425247.2014.927864","article-title":"Intravitreal drug delivery in retinal disease: are we out of our depth?","volume":"11","author":"Thakur","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"361","key":"10.1016\/j.ymeth.2025.02.003_b0320","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2023.07.055","article-title":"Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery","volume":"1","author":"Qi","year":"2023","journal-title":"J. Control. Release"},{"issue":"13","key":"10.1016\/j.ymeth.2025.02.003_b0325","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3762\/bjnano.13.98","article-title":"Microneedle-based ocular drug delivery systems \u2013 recent advances and challenges","volume":"24","author":"Gadzi\u0144ski","year":"2022","journal-title":"Beilstein J. Nanotechnol."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0330","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1007\/s12325-023-02541-x","article-title":"Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics","volume":"40","author":"Mascarenhas","year":"2023","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0335","first-page":"175","article-title":"Ocular prodrugs: Attributes and challenges. Asian","volume":"16","author":"kour","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0340","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s13346-021-01043-z","article-title":"In vitro dissolution testing models of ocular implants for posterior segment drug delivery","volume":"12","author":"Adrianto","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0345","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br. J. Ophthalmol."},{"issue":"10432","key":"10.1016\/j.ymeth.2025.02.003_b0350","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ymeth.2025.02.003_b0355","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"20","author":"Ehlken","year":"2017","journal-title":"Clin. Ophthalmol."},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0360","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J. Fr. Ophtalmol."},{"issue":"10411","key":"10.1016\/j.ymeth.2025.02.003_b0365","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"10411","key":"10.1016\/j.ymeth.2025.02.003_b0370","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"issue":"10432","key":"10.1016\/j.ymeth.2025.02.003_b0375","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymeth.2025.02.003_b0380","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2020.07.002","article-title":"A Randomized Controlled Trial Comparing Subconjunctival Injection to Direct Scleral Application of Mitomycin C in Trabeculectomy","volume":"220","author":"Do","year":"2020","journal-title":"Am. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0385","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0390","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ICL.0000000000000292","article-title":"Subtenon Injections of Ranibizumab Arrest Growth in Early Recurrent Pterygium","volume":"43","author":"Rose","year":"2017","journal-title":"Eye Contact Lens"},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0395","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ymeth.2025.02.003_b0400","unstructured":"Cureus | Efficacy and Safety of the Subtenon Injection of 0.01% Mitomycin C-augmented Trabeculectomy | Article [Internet]. [cited 2024 Jul 15]. Available from: https:\/\/www.cureus.com\/articles\/258537-efficacy-and-safety-of-the-subtenon-injection-of-001-mitomycin-c-augmented-trabeculectomy#!\/."},{"issue":"122","key":"10.1016\/j.ymeth.2025.02.003_b0405","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.addr.2017.04.001","article-title":"Nanoparticles for drug delivery to the anterior segment of the eye","volume":"1","author":"Janagam","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymeth.2025.02.003_b0410","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/IJG.0000000000000107","article-title":"The Blood-Aqueous Barrier in Health and Disease","volume":"23","author":"Coca-Prados","year":"2014","journal-title":"J. Glaucoma"},{"issue":"1187","key":"10.1016\/j.ymeth.2025.02.003_b0415","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/postmj\/qgae046","article-title":"Advances in the study of microparticles in diabetic retinopathy","volume":"100","author":"Hou","year":"2024","journal-title":"Postgrad. Med. J."},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b0420","first-page":"1963","article-title":"Chitosan-Based Nanoparticles as Effective Drug Delivery Systems-A review","volume":"28","author":"Jafernik","year":"2023","journal-title":"Mol Basel Switz."},{"key":"10.1016\/j.ymeth.2025.02.003_b0425","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.ymeth.2025.02.003_b0430","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1167\/iovs.17-22160","article-title":"Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers","volume":"58","author":"Li","year":"2017","journal-title":"Investig Opthalmology vis Sci."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0435","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-023-42189-3","article-title":"Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina","volume":"14","author":"Gautam","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymeth.2025.02.003_b0440","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-023-02838-z","article-title":"Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial","author":"Rao","year":"2023","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0445","unstructured":"Biodegradable microspheres come into sight: A promising biomaterial for delivering drug to the posterior segment of the eyeball - PMC [Internet]. [cited 2024 Jul 15]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11237977\/."},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0450","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3109\/02713689508995797","article-title":"Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres","volume":"14","author":"Giordano","year":"1995","journal-title":"Curr. Eye Res."},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b0455","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/10611869409015909","article-title":"Polysulfone Capillary Fiber for Intraocular Drug Delivery: In Vitro and in Vivo Evaluations","volume":"2","author":"Rahimy","year":"1994","journal-title":"J. Drug Target."},{"issue":"10","key":"10.1016\/j.ymeth.2025.02.003_b0460","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1167\/iovs.16-21334","article-title":"Evaluation of the Toxicity of Intravitreally Injected PLGA Microspheres and Rods in Monkeys and Rabbits: Effects of Depot Size on Inflammatory Response","volume":"58","author":"Thackaberry","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0465","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069625","article-title":"Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners","volume":"13","author":"Yiallouridou","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0470","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ogla.2018.06.005","article-title":"A Survey of Patient Perceptions and Preferences for Glaucoma Treatment with Intravitreal Injections","volume":"1","author":"Torres","year":"2018","journal-title":"Ophthalmol Glaucoma."},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0475","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1007\/s11095-015-1717-z","article-title":"A New Vision for the Eye: Unmet Ocular Drug Delivery Needs","volume":"32","author":"Rivers","year":"2015","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0480","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/jps.21987","article-title":"A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases","volume":"99","author":"Choonara","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b0485","doi-asserted-by":"crossref","first-page":"598.e1","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and Adherence With Topical Glaucoma Therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0490","article-title":"Preclinical Safety and Tolerability of Repeated Intracameral Travoprost Implant (OTX-TIC) Administrations","author":"Patel","year":"2023","journal-title":"In"},{"key":"10.1016\/j.ymeth.2025.02.003_b0495","unstructured":"Ophthalmology Times [Internet]. 2024 [cited 2024 Jul 16]. ASCRS 2024: Phase 2 trial of travoprost intracameral implant in open-angle glaucoma or ocular hypertension. Available from: https:\/\/www.ophthalmologytimes.com\/view\/ascrs-2024-phase-2-trial-of-travoprost-intracameral-implant-in-open-angle-glaucoma-or-ocular-hypertension."},{"key":"10.1016\/j.ymeth.2025.02.003_b0500","doi-asserted-by":"crossref","unstructured":"Subhash NE, Nair S, Srinivas SP, Theruveethi N, Bhandary SV, Guru B. Development of a biodegradable polymer-based implant to release dual drugs for post-operative management of cataract surgery. Drug Deliv Transl Res [Internet]. 2024 May 2 [cited 2024 Jul 16]; Available from: Doi: 10.1007\/s13346-024-01604-y.","DOI":"10.21203\/rs.3.rs-3987612\/v1"},{"key":"10.1016\/j.ymeth.2025.02.003_b0505","article-title":"U.S. Phase 1 Study of Intravitreal Axitinib Implant (OTX-TKI) for Neovascular Age-related Macular Degeneration","author":"Moshfeghi","year":"2023","journal-title":"In"},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0510","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1021\/acsomega.0c05535","article-title":"Redox-Responsive Hyaluronic Acid-Based Nanogels for the Topical Delivery of the Visual Chromophore to Retinal Photoreceptors","volume":"6","author":"Laradji","year":"2021","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.ymeth.2025.02.003_b0515","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3390\/pharmaceutics13111781","article-title":"Hyaluronan-Cholesterol Nanogels for the Enhancement of the Ocular Delivery of Therapeutics","volume":"13","author":"Zoratto","year":"2021","journal-title":"Pharmaceutics."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0520","article-title":"Polysaccharide-based nanogels and ocular drug delivery: The emerging nanocarrier for crossing blood retinal barrier","volume":"1","author":"Modi","year":"2023","journal-title":"Carbohydr. Polym. Technol. Appl."},{"issue":"26","key":"10.1016\/j.ymeth.2025.02.003_b0525","article-title":"Trimethyl chitosan-hyaluronic acid nano-polyplexes for intravitreal VEGFR-2 siRNA delivery: Formulation and in vivo efficacy evaluation","volume":"1","author":"Chaharband","year":"2020","journal-title":"Nanomedicine Nanotechnol Biol Med."},{"issue":"576","key":"10.1016\/j.ymeth.2025.02.003_b0530","article-title":"New nanoparticles for topical ocular delivery of erythropoietin","volume":"25","author":"Silva","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymeth.2025.02.003_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120491","article-title":"Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity","volume":"267","author":"Ingrole","year":"2021","journal-title":"Biomaterials"},{"issue":"16","key":"10.1016\/j.ymeth.2025.02.003_b0540","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.3390\/polym13162815","article-title":"A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications","volume":"13","author":"Aldawood","year":"2021","journal-title":"Polymers"},{"issue":"201","key":"10.1016\/j.ymeth.2025.02.003_b0545","article-title":"Microneedles for advanced ocular drug delivery","volume":"1","author":"Glover","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0550","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.ymeth.2025.02.003_b0555","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1167\/iovs.14-15257","article-title":"Intrastromal Delivery of Bevacizumab Using Microneedles to Treat Corneal Neovascularization","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.ymeth.2025.02.003_b0560","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/tvst.12.3.31","article-title":"Suprachoroidal Delivery in Rats and Guinea Pigs Using a High-Precision Microneedle Injector","volume":"12","author":"Hejri","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"16","key":"10.1016\/j.ymeth.2025.02.003_b0565","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","volume":"13","author":"Yiu","year":"2020","journal-title":"Mol Ther - Methods Clin Dev."},{"issue":"80","key":"10.1016\/j.ymeth.2025.02.003_b0570","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.actbio.2018.09.039","article-title":"Intracorneal injection of a detachable hybrid microneedle for sustained drug delivery","volume":"15","author":"Lee","year":"2018","journal-title":"Acta Biomater."},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0575","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1038\/s41467-018-06981-w","article-title":"Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery","volume":"6","author":"Than","year":"2018","journal-title":"Nat. Commun."},{"issue":"165","key":"10.1016\/j.ymeth.2025.02.003_b0580","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejpb.2021.05.022","article-title":"Long-acting nanoparticle-loaded bilayer microneedles for protein delivery to the posterior segment of the eye","volume":"1","author":"Wu","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0585","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/jop.2019.0034","article-title":"Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications","volume":"36","author":"Perez","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0590","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ophtha.2011.07.006","article-title":"Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for Treating Noninfectious Anterior Uveitis","volume":"119","author":"Cohen","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b0595","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/jop.2019.0081","article-title":"Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules","volume":"36","author":"Molokhia","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"277","key":"10.1016\/j.ymeth.2025.02.003_b0600","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2018.03.001","article-title":"Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle","volume":"10","author":"Jung","year":"2018","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0605","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41598-020-58822-w","article-title":"Ultrasonically and Iontophoretically Enhanced Drug-Delivery System Based on Dissolving Microneedle Patches","volume":"10","author":"Bok","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0610","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejpb.2014.04.018","article-title":"In vitro permeability of a model protein across ocular tissues and effect of iontophoresis on the transscleral delivery","volume":"88","author":"Tratta","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ymeth.2025.02.003_b0615","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejpb.2021.02.007","article-title":"Next-generation contact lenses: Towards bioresponsive drug delivery and smart technologies in ocular therapeutics","volume":"161","author":"Chaudhari","year":"2021","journal-title":"Eur J Pharm Biopharm off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV."},{"key":"10.1016\/j.ymeth.2025.02.003_b0620","article-title":"Ranibizumab port delivery system in neovascular age-related macular degeneration","volume":"14","author":"Chandrasekaran","year":"2022","journal-title":"Ther Adv Ophthalmol."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0625","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.12.6.3","article-title":"A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates","volume":"12","author":"Rotenstreich","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"3","key":"10.1016\/j.ymeth.2025.02.003_b0630","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ICU.0000000000000851","article-title":"Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"33","author":"Adamis","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0635","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0640","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/IAE.0000000000002614","article-title":"EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL","volume":"40","author":"Bantseev","year":"2020","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ymeth.2025.02.003_b0645","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0650","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.oret.2023.11.002","article-title":"Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration","volume":"8","author":"Brown","year":"2024","journal-title":"Ophthalmol Retina."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0655","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamaophthalmol.2022.2495","article-title":"Ranibizumab Injection (Susvimo) Implant Septum Dislodgement in a Patient With Neovascular Age-Related Macular Degeneration","volume":"140","author":"Timmons","year":"2022","journal-title":"JAMA Ophthalmol."},{"issue":"9","key":"10.1016\/j.ymeth.2025.02.003_b0660","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40942-023-00446-z","article-title":"Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists","volume":"30","author":"Sharma","year":"2023","journal-title":"Int J Retina Vitr."},{"key":"10.1016\/j.ymeth.2025.02.003_b0665","unstructured":"Genentech: Press Releases | Monday, Jul 8, 2024 [Internet]. [cited 2024 Jul 8]. Available from: https:\/\/www.gene.com\/media\/press-releases\/15031\/2024-07-08\/genentech-to-reintroduce-susvimo-for-peo."},{"key":"10.1016\/j.ymeth.2025.02.003_b0670","unstructured":"Mahnama A, Raisee M, Hashemian TS, Nourbakhsh A, Marjanian R. A Study on Implantable Micropump Systems for Drug Delivery. 2011."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0675","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10544-009-9313-9","article-title":"A passive MEMS drug delivery pump for treatment of ocular diseases","volume":"11","author":"Lo","year":"2009","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.ymeth.2025.02.003_b0680","doi-asserted-by":"crossref","unstructured":"Li PY, Shih J, Lo R, Adams B, Agrawa R, Saati S, et al. An electrochemical intraocular drug delivery device. In: 2007 IEEE 20th International Conference on Micro Electro Mechanical Systems (MEMS) [Internet]. 2007 [cited 2024 Jul 29]. p. 15\u20138. Available from: https:\/\/ieeexplore.ieee.org\/document\/4433047.","DOI":"10.1109\/MEMSYS.2007.4433047"},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b0685","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.3.3.8","article-title":"One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study","volume":"3","author":"Guti\u00e9rrez-Hern\u00e1ndez","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0690","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.3.6.5","article-title":"Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema","volume":"3","author":"Humayun","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0695","unstructured":"Evaluation of the Performance, Biocompatibility and Safety of a New Posterior MicroPump Drug Delivery System [Internet]. [cited 2024 Jul 29]. Available from: https:\/\/www.researchgate.net\/publication\/296087098_Evaluation_of_the_Performance_Biocompatibility_and_Safety_of_a_New_Posterior_MicroPump_Drug_Delivery_System."},{"issue":"196","key":"10.1016\/j.ymeth.2025.02.003_b0700","article-title":"Smart contact lens systems for ocular drug delivery and therapy","volume":"1","author":"Kim","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"93","key":"10.1016\/j.ymeth.2025.02.003_b0705","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.msec.2018.07.065","article-title":"Inner layer-embedded contact lenses for ion-triggered controlled drug delivery","volume":"1","author":"Zhu","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.9.4.1","article-title":"Stimulus-Responsive Contact Lens for IOP Measurement or Temperature-Triggered Drug Release","volume":"9","author":"Lee","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0715","article-title":"Wireless smart contact lens for diabetic diagnosis and therapy","author":"Keum","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymeth.2025.02.003_b0720","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf7194","article-title":"Smart contact lens and transparent heat patch for remote monitoring and therapy of chronic ocular surface inflammation using mobiles","author":"Jang","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0725","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1038\/s41467-022-34597-8","article-title":"Wireless theranostic smart contact lens for monitoring and control of intraocular pressure in glaucoma","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0730","article-title":"Contact lens as an emerging platform for ophthalmic drug delivery: A systematic review","volume":"18","author":"Yang","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0735","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001104","article-title":"Ranibizumab port delivery system: a clinical perspective","volume":"7","author":"Eichenbaum","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"key":"10.1016\/j.ymeth.2025.02.003_b0740","doi-asserted-by":"crossref","unstructured":"Wan C rei, Kapik B, Wykoff CC, Henry CR, Barakat MR, Shah M, et al. Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders. Transl Vis Sci Technol. 2020 Oct 22;9(11):27.","DOI":"10.1167\/tvst.9.11.27"},{"key":"10.1016\/j.ymeth.2025.02.003_b0745","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/780634","article-title":"Drug Delivery Implants in the Treatment of Vitreous Inflammation","volume":"2013","author":"Wang","year":"2013","journal-title":"Mediators Inflamm."},{"issue":"13","key":"10.1016\/j.ymeth.2025.02.003_b0750","first-page":"4332","article-title":"I-VationTM TA: 24-month Clinical Results of the Phase I Safety and Preliminary Efficacy Study","volume":"50","author":"Dugel","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0755","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.oret.2023.03.001","article-title":"Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration","volume":"7","author":"Freeman","year":"2023","journal-title":"Ophthalmol Retina."},{"key":"10.1016\/j.ymeth.2025.02.003_b0760","unstructured":"Torkashvand A, Izadian A, Hajrasouliha A. Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions. Surv Ophthalmol [Internet]. 2024 Jul 8 [cited 2024 Jul 23]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0039625724000766."},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0765","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40942-021-00325-5","article-title":"Pipeline therapies for neovascular age related macular degeneration","volume":"1","author":"Arepalli","year":"2021","journal-title":"Int J Retina Vitr."},{"key":"10.1016\/j.ymeth.2025.02.003_b0770","unstructured":"Study Details | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) | ClinicalTrials.gov [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05066230."},{"key":"10.1016\/j.ymeth.2025.02.003_b0775","unstructured":"Study Details | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. | ClinicalTrials.gov [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04049266."},{"key":"10.1016\/j.ymeth.2025.02.003_b0780","unstructured":"Study Details | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | ClinicalTrials.gov [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04603937."},{"key":"10.1016\/j.ymeth.2025.02.003_b0785","unstructured":"Study Details | A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | ClinicalTrials.gov [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04611152."},{"key":"10.1016\/j.ymeth.2025.02.003_b0790","unstructured":"Study Details | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) | ClinicalTrials.gov [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04964089."},{"key":"10.1016\/j.ymeth.2025.02.003_b0795","unstructured":"Wykoff CC. Tarcocimab Tedromer for Diabetic Retinopathy: Primary Endpoint Efficacy and Safety Outcomes of the GLOW Phase 3 Pivotal Study."},{"issue":"16","key":"10.1016\/j.ymeth.2025.02.003_b0800","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses","volume":"3","author":"Ghoraba","year":"2022","journal-title":"Clin Ophthalmol Auckl NZ."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0805","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/pharmaceutics14050998","article-title":"Ocular Barriers and Their Influence on Gene Therapy Products Delivery","volume":"14","author":"Leclercq","year":"2022","journal-title":"Pharmaceutics."},{"issue":"3","key":"10.1016\/j.ymeth.2025.02.003_b0810","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Retinal gene therapy in X-linked retinitis pigmentosa caused by mutations in RPGR: Results at 6 months in a first in human clinical trial","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0815","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/pharmaceutics15061622","article-title":"Transscleral Delivery of Dexamethasone-Loaded Microparticles Using a Dissolving Microneedle Array","volume":"15","author":"Fitaihi","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ymeth.2025.02.003_b0820","doi-asserted-by":"crossref","unstructured":"Ding K, Shen J, Hafiz Z, Hackett SF, Silva RL e, Khan M, et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J. Clin. Invest. 2019 Nov 1;129(11):4901\u201311.","DOI":"10.1172\/JCI129085"},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0825","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017140","article-title":"Ab-Externo AAV-Mediated Gene Delivery to the Suprachoroidal Space Using a 250 Micron Flexible Microcatheter","volume":"6","author":"Peden","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ymeth.2025.02.003_b0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115239","article-title":"First-in-Human Trial of a Novel Suprachoroidal Retinal Prosthesis","volume":"9","author":"Ayton","year":"2014","journal-title":"PLoS One"},{"issue":"13\u201314","key":"10.1016\/j.ymeth.2025.02.003_b0835","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"issue":"279","key":"10.1016\/j.ymeth.2025.02.003_b0840","article-title":"Implantation and long-term assessment of the stability and biocompatibility of a novel 98 channel suprachoroidal visual prosthesis in sheep","volume":"1","author":"Eggenberger","year":"2021","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.ymeth.2025.02.003_b0845","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41434-021-00233-1","article-title":"Proteosomal Degradation Impairs Transcytosis of AAV vectors from Suprachoroidal Space to Retina","volume":"28","author":"Ding","year":"2021","journal-title":"Gene Ther."},{"issue":"16","key":"10.1016\/j.ymeth.2025.02.003_b0850","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","volume":"21","author":"Yiu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymeth.2025.02.003_b0855","unstructured":"Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma - Aura Biosciences [Internet]. [cited 2024 Jul 30]. Available from: https:\/\/ir.aurabiosciences.com\/news-releases\/news-release-details\/aura-biosciences-announces-first-patient-dosed-global-phase-3\/."},{"key":"10.1016\/j.ymeth.2025.02.003_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2024.05.004","article-title":"Biomechanical considerations for optimising subretinal injections","author":"L\u2019Abbate","year":"2024","journal-title":"Surv Ophthalmol [internet]."},{"key":"10.1016\/j.ymeth.2025.02.003_b0865","unstructured":"PentaVision [Internet]. [cited 2024 Jul 22]. Current Status of Subretinal Delivery Devices. Available from: https:\/\/retinalphysician.com\/issues\/2023\/april\/current-status-of-subretinal-delivery-devices\/."},{"key":"10.1016\/j.ymeth.2025.02.003_b0870","unstructured":"Pandolfi B. A minimally invasive trans-choroidal subretinal cannulation system based on a novel resistance sensing mechanical principle of injection [Internet]. healthylongevitychallenge.org. [cited 2024 Jul 22]. Available from: https:\/\/healthylongevitychallenge.org\/winners\/a-minimally-invasive-trans-choroidal-subretinal-cannulation-system-based-on-a-novel-resistance-sensing-mechanical-principle-of-injection\/."},{"key":"10.1016\/j.ymeth.2025.02.003_b0875","unstructured":"Wasnik VB, Thool AR. Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials. Cureus. 14(9):e29533."},{"key":"10.1016\/j.ymeth.2025.02.003_b0880","doi-asserted-by":"crossref","unstructured":"He X, Fu Y, Ma L, Yao Y, Ge S, Yang Z, et al. AAV for Gene Therapy in Ocular Diseases: Progress and Prospects. Research. 6:0291.","DOI":"10.34133\/research.0291"},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0885","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","article-title":"Seeing the Light after 25 Years of Retinal Gene Therapy","volume":"24","author":"Trapani","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymeth.2025.02.003_b0890","article-title":"Behind the scenes of the world\u2019s first commercial stem-cell therapy","author":"Abbott","year":"2015","journal-title":"Nature [internet]."},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0895","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/sctm.17-0003","article-title":"Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union","volume":"7","author":"Pellegrini","year":"2017","journal-title":"Stem Cells Transl. Med."},{"issue":"10","key":"10.1016\/j.ymeth.2025.02.003_b0900","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.ophtha.2016.06.041","article-title":"Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier","volume":"123","author":"MacLaren","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymeth.2025.02.003_b0905","doi-asserted-by":"crossref","unstructured":"Ahmed I, Jr RJJ, Singh MS. Pluripotent stem cell therapy for retinal diseases. Ann. Transl. Med. 2021 Aug; 9(15):1279\u20131279.","DOI":"10.21037\/atm-20-4747"},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b0910","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41591-022-01862-8","article-title":"Regenerative and restorative medicine for eye disease","volume":"28","author":"Van Gelder","year":"2022","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ymeth.2025.02.003_b0915","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ICU.0000000000001034","article-title":"Cell therapy for retinal disease","volume":"35","author":"Yalla","year":"2024","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"11","key":"10.1016\/j.ymeth.2025.02.003_b0920","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.ophtha.2018.04.037","article-title":"Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration","volume":"125","author":"Mehat","year":"2018","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0925","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/jcm9072217","article-title":"HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration","volume":"9","author":"Sugita","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymeth.2025.02.003_b0930","unstructured":"Study Details | Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD | ClinicalTrials.gov [Internet]. [cited 2024 Sep 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02590692."},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b0935","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a novel siRNA for the treatment of dry eye disease","volume":"27","author":"Moreno-Monta\u00f1\u00e9s","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0940","article-title":"Efficient ocular delivery of siRNA via pH-sensitive vehicles for corneal neovascularization inhibition","volume":"29","author":"Cao","year":"2023","journal-title":"Int J Pharm x."},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0945","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/dtb.2023.000004","article-title":"Small interfering RNA (siRNA)-based therapeutics","volume":"61","author":"Patterson","year":"2023","journal-title":"Drug Ther. Bull."},{"issue":"40","key":"10.1016\/j.ymeth.2025.02.003_b0950","doi-asserted-by":"crossref","first-page":"15461","DOI":"10.1039\/C7NR03142D","article-title":"Therapeutic effects of a novel siRNA-based anti-VEGF (siVEGF) nanoball for the treatment of choroidal neovascularization","volume":"9","author":"Ryoo","year":"2017","journal-title":"Nanoscale"},{"issue":"5","key":"10.1016\/j.ymeth.2025.02.003_b0955","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: State-of-the-Art and Future Perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.ymeth.2025.02.003_b0960","first-page":"111","article-title":"Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma","volume":"90","author":"Lu","year":"2017","journal-title":"Yale J. Biol. Med."},{"issue":"3","key":"10.1016\/j.ymeth.2025.02.003_b0965","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3390\/ijms24032753","article-title":"High-Capacity Mesoporous Silica Nanocarriers of siRNA for Applications in Retinal Delivery","volume":"24","author":"Ultimo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymeth.2025.02.003_b0970","article-title":"A potent bioreducible ionizable lipid nanoparticle enables siRNA delivery for retinal neovascularization inhibition","volume":"199","author":"Cao","year":"2024","journal-title":"Eur J Pharm Biopharm off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b0975","article-title":"Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing","volume":"1","author":"Hern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0980","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.ymeth.2025.02.003_b0985","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/gt.2014.39","article-title":"CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype","volume":"21","author":"Burnight","year":"2014","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b0990","article-title":"CRISPR Technology for Ocular Angiogenesis","volume":"22","author":"Chung","year":"2020","journal-title":"Front Genome Ed."},{"issue":"19","key":"10.1016\/j.ymeth.2025.02.003_b0995","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.3390\/ijms231911482","article-title":"CRISPR\/Cas9\u2014A Promising Therapeutic Tool to Cure Blindness: Current Scenario and Future Prospects","volume":"23","author":"Ahmad","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b1000","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41433-022-02169-1","article-title":"The application and progression of CRISPR\/Cas9 technology in ophthalmological diseases","volume":"37","author":"Hu","year":"2022","journal-title":"Eye"},{"issue":"40","key":"10.1016\/j.ymeth.2025.02.003_b1005","first-page":"135","article-title":"The power and the promise of CRISPR\/Cas9 genome editing for clinical application with gene therapy","volume":"4","author":"Guo","year":"2021","journal-title":"J. Adv. Res."},{"issue":"22","key":"10.1016\/j.ymeth.2025.02.003_b1010","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1111\/febs.16771","article-title":"Therapeutic Applications of CRISPR\/Cas9 Gene Editing Technology for the Treatment of Ocular Diseases","volume":"290","author":"Sundaresan","year":"2023","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b1015","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/biom14080903","article-title":"Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress","volume":"14","author":"Liu","year":"2024","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b1020","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/ijms22042092","article-title":"Gene Correction Recovers Phagocytosis in Retinal Pigment Epithelium Derived from Retinitis Pigmentosa-Human-Induced Pluripotent Stem Cells","volume":"22","author":"Artero-Castro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.ymeth.2025.02.003_b1025","first-page":"81","article-title":"Restoration of RPGR expression in vivo using CRISPR\/Cas9 gene editing","volume":"29","author":"Gumerson","year":"2021","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.ymeth.2025.02.003_b1030","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/IAE.0000000000002125","article-title":"CLINICAL AND GENETIC CHARACTERISTICS OF MALE PATIENTS WITH RPGR-ASSOCIATED RETINAL DYSTROPHIES: A Long-Term Follow-up Study","volume":"39","author":"Talib","year":"2019","journal-title":"Retina"},{"issue":"3\u20134","key":"10.1016\/j.ymeth.2025.02.003_b1035","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00439-022-02448-7","article-title":"The genetic and phenotypic landscapes of Usher syndrome: from disease mechanisms to a new classification","volume":"141","author":"Delmaghani","year":"2022","journal-title":"Hum. Genet."},{"issue":"19","key":"10.1016\/j.ymeth.2025.02.003_b1040","doi-asserted-by":"crossref","first-page":"11669","DOI":"10.3390\/ijms231911669","article-title":"New CRISPR Tools to Correct Pathogenic Mutations in Usher Syndrome","volume":"23","author":"Major","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b1045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaophthalmol.2022.0167","article-title":"FDA Facilitating Innovation of Ophthalmic Devices While Balancing the Need for Safety and Effectiveness","volume":"140","author":"Nguyen","year":"2022","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"10.1016\/j.ymeth.2025.02.003_b1050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11095-019-2577-8","article-title":"Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology","volume":"36","author":"Rowe-Rendleman","year":"2019","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ymeth.2025.02.003_b1055","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1089\/jop.2023.0071","article-title":"Eyes on the Prize: Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval","volume":"39","author":"Hirani","year":"2023","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ymeth.2025.02.003_b1060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA Approval and Regulation of Pharmaceuticals, 1983-2018","volume":"323","author":"Darrow","year":"2020","journal-title":"J. Am. Med. Assoc."}],"container-title":["Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202325000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202325000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T13:46:25Z","timestamp":1740231985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046202325000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":212,"alternative-id":["S1046202325000362"],"URL":"https:\/\/doi.org\/10.1016\/j.ymeth.2025.02.003","relation":{},"ISSN":["1046-2023"],"issn-type":[{"value":"1046-2023","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latest trends & strategies in ocular drug delivery","name":"articletitle","label":"Article Title"},{"value":"Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymeth.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}